Journal article icon

Journal article

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.

Abstract:

OBJECTIVES: To investigate baricitinib (LY3009104, formerly INCB028050), a novel, oral inhibitor of JAK1/JAK2 in patients with moderate to severe rheumatoid arthritis (RA) despite treatment with methotrexate. METHODS: In this phase IIb study, 301 patients were randomised 2:1:1:1:1 to receive once daily doses of placebo or 1, 2, 4 or 8 mg baricitinib for 12 weeks. Patients assigned to 2, 4 and 8 mg baricitinib continued blinded treatment for an additional 12 weeks. Patients assigned to placebo...

Expand abstract

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, NDORMS
Role:
Author
Expand authors...
Journal:
Annals of the rheumatic diseases
Volume:
74
Issue:
2
Pages:
333-340
Publication date:
2015-02-05
DOI:
EISSN:
1468-2060
ISSN:
0003-4967
URN:
uuid:9c64cc28-17e5-4b37-82c8-16bce83442b3
Source identifiers:
491894
Local pid:
pubs:491894

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP